The White House coronavirus response coordinator, in an email to senior colleagues, said the way the administration initially distributed supplies of the promising new drug remdesivir shouldn’t happen again, according to an email reviewed by The Wall Street Journal. Dr. Deborah Birx, in the May 7 email sent to fellow Trump administration task force members and other senior officials, said her colleagues would review how the decision-making led to a “misalignment” of the drug’s allocation in the days after the government began...

Source: Wall Street Journal May 12, 2020 01:30 UTC